IXICO announces strategic collaboration with leading pharmaceutical company to develop and pilot an adapted version of Assessa® for the clinical management of multiple sclerosis

IXICO today announces that it has entered into a strategic collaboration with a leading pharmaceutical company and independent expert clinical centres in the management of multiple sclerosis.

Under the terms of the multi-stage collaboration, IXICO will develop an adapted version of Assessa®, its CE marked digital healthcare platform, to assist in the monitoring and management of people receiving approved pharmaceutical treatments for multiple sclerosis (‘MS’) in the EU and Canada. The project will start in October 2015 and it is anticipated that the digital platform will be deployed in a clinical setting in 2016.

By |2017-10-10T16:30:34+00:009 October 2015|Collaboration|